Epstein-Barr virus post-transplant lymphoproliferative disease (PTLD) after hematopoietic stem cell transplantation

Autor:	Jia Chen, Yuhua Ru, Depei Wu
Rok vydání:	2018
Předmět:	Epstein-Barr Virus Infections Herpesvirus 4 Human Transplantation Conditioning medicine.medical_treatment Lymphoproliferative disorders Viremia Cord Blood Stem Cell Transplantation Hematopoietic stem cell transplantation medicine.disease_cause 03 medical and health sciences 0302 clinical medicine HLA Antigens Risk Factors hemic and lymphatic diseases medicine Humans Transplantation Homologous Epstein–Barr virus infection business.industry Hematopoietic Stem Cell Transplantation Disease Management Hematology General Medicine medicine.disease Epstein–Barr virus Lymphoproliferative Disorders Tissue Donors surgical procedures operative 030220 oncology & carcinogenesis Immunology Virus Activation Rituximab Symptom Assessment business T-Lymphocytes Cytotoxic 030215 immunology medicine.drug
Zdroj:	European Journal of Haematology. 101:283-290
ISSN:	0902-4441
DOI:	10.1111/ejh.13131
Popis:	Epstein-Barr virus (EBV) viremia and post-transplant lymphoproliferative disease (PTLD) are severe complications after hematopoietic stem cell transplantation (HSCT). A series of risk factors have been found to predict EBV viremia and PTLD, including the T-cell depletion, reduced intensity conditioning, and alternative donor. The rituximab pre-emptive therapy could improve PTLD prognosis significantly, but the trigger of initiating rituximab pre-emptive therapy has not been well established. Additionally, EBV-specific cytotoxic T cell (CTL) is a promising approach to treat EBV-PTLD.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0259a7e9f2e6507051af93bc30eba3d0 https://doi.org/10.1111/ejh.13131 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.